Chemotherapy for advanced pancreatic cancer: The history is changing

Tumori

Volumn 84, Issue 3, 1998, Pages 308-311

  Graziano, Francesco ^a   Catalano, Giuseppina ^a   Cascinu, Stefano ^a,b  

^a Azienda Ospedaliera Osp S S   (Italy)

^b Ospedale di Muraglia   (Italy)

Author keywords

Chemotherapy in the treatment of advanced pancreatic cancer; Pancreatic cancer

Indexed keywords

ANTIANDROGEN; ANTIESTROGEN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GONADORELIN AGONIST; IRINOTECAN; MITOMYCIN; STREPTOZOCIN; TAMOXIFEN; TOPOTECAN;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DISEASE COURSE; PANCREAS ADENOCARCINOMA; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0031809921     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169808400304     Document Type: Review

References (30)

1. Ahlgren J.D.: Chemotherapy for pancreatic cancer. Cancer, 78: 654-663, 1996.
2. Ardalan B., Singh G., Silbermann H.: A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced colorectal and pancreatic cancer. J. Clin. Oncol., 6: 1053-1058, 1988.
3. Auerbach M., Wampler G.L., Lokich J.J., Fryer D., Fryer J.G., Ahlgren J.D.: Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program study. Ann. Oncol., 8: 439-444, 1997.
4. Burris H.A. III, Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarasoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15: 2403-2413, 1997.
5. Carmichael J., Fink U., Russell R.C.G., Spittle M.F., Harris A., Spiessl G.: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer, 73: 101-105, 1995.
6. Casper E.S., Green M.R., Kelsen D.P., Heelan R.T., Brown T.D., Flombaum C.D.: Phase II trial of gemcitabine in patients with adenocarcinoma of the pancreas. Invest. New Drugs, 12: 29-35, 1994.
7. Cullinan S., Moertel C.G., Wieand H.S., Schutt A.J., Krook J.E., Foley F.F., Norris B.D., Kardinal K.G., Tschetter L.K., Barlow J.F.: A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin and cisplatin. Cancer 65: 2207-2212, 1989.
8. Evans T.R.J., Lofts F.J., Mansi J.L., Glees J.P., Dalgleish A.G., Knight M.J.: A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br. J. Cancer, 73: 1260-1264, 1996.
9. Glimelius B., Hoffman K., Graf W., Haglund U., Nyren L., Pahlman L., Sjoden P.O.: Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann. Oncol., 6: 267-274, 1995.
10. Glimelius B., Hoffman K., Sjoden P.O., Jacobsson G., Sellstrom H., Enander L.K., Linne T., Svensson C.: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol., 7: 593-600, 1996.
11. Lionetto R., Pugliese V., Bruzzi P.: No standard treatment is available for advanced pancreatic cancer. Eur. J. Cancer, 6: 882-887, 1995.
12. Mallinson C.N., Rake M.O., Cocking J.B., Fox C.A., Cwynarski M.T., Diffey B.L., Jackson G.A., Hanley J., Wass V.J.: Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br. Med. J., 281: 1589-1591, 1980.
13. Moller Jensen O., Estève J., Moller H., Renard H.: Cancer in the European Community and its member states. Eur. J. Cancer, 26: 1176-1256, 1990.
14. Moore M.: Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer, 78: 633-638, 1996.
15. Oster M.W., Gray R., Panasci L., Perry M.C.: Chemotherapy for advanced pancreatic cancer: a comparison of 5-fluorouracil, adriamycin, mitomycin (FAM) with 5-fluorouracil, streptozotocin, mitomycin (FSM). Cancer, 57: 29-33, 1986.
16. Palmer K.R., Kerr M., Knowles G., Cull A., Carter D.C., Leonard R.C.: Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br. J. Surg., 81: 882-885, 1994.
17. Parker S.L., Tong T., Bold S., Wingo P.A.: Cancer statistics, 1997. CA Cancer Clin., 47: 5-27, 1997.
18. Popescu R.A., Cunningham D.: Chemotherapy for advanced pancreatic cancer. Some light at the end of the tunnel? Ann. Oncol., 8: 415-416, 1997.
19. Rothenberg L.M.: Abbruzzese J.L., Moore M., Portenoy R.K., Robertson J.M., Wanebo H.J.: A rationale for expanding the end points for clinical trials in advanced pancreatic carcinoma. Cancer, 78: 627-632, 1996.
20. Rothenberg L.M., Moore M.J., Cripps M.C., Andersen J.S., Portenoy R.K., Burris H.A., Green M.R., Tarasoff P.G., Brown T.D., Casper E.S., Storniolo A.M., Von Hoff D.D.: A phase II trial of gemcitabine in patients with 5FU-refractory pancreas cancer. Ann. Oncol., 7: 347-353, 1996.
21. Rothman H., Cantrell J.E., Lokich J., Difino S., Harvey J., Ahlgren J.: Continuous infusion of 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study. Cancer, 68: 264-268, 1991.
22. Rougier P., De Forni M., Adenis A., Ducreaux M., Djazouli K., Adams D., Bonnterre J., Clouet P., Blanc C., Bayssas M., Armand J.P.: Phase II study of taxotere in pancreatic adenocarcinoma (Abstract). Proc. Am. Soc. Clin. Oncol., 13: 200, 1994.
23. Scher M.N., Kosierowski R., Lusch C., Alexander R., Fox S., Redi I., Green F., Raskay B., Amfoh K., Engstrom P.F., O'Dwyer P.J.: Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest. New Drugs, 13: 347-354, 1996.
24. Schnall S., MacDonald J.S.: Chemotherapy of adenocarcinoma of the pancreas. Semin. Oncol., 23: 220-228, 1996.
25. Taylor I.: Should further studies of chemotherapy be carried out in pancreatic cancer? Eur. J. Cancer, 29: 1076-1078, 1993.
26. Tian E., Ardalan B., Benedetto P., Feun L., Morrel L., Waldan S.: A phase II study of a short-term protracted infusion of high dose 5-fluorouracil (FU) with leucovorin (LV) and low dose N-(phosphonacetyl)-L-aspartic acid (PALA) in pancreatic carcinoma (Abstract). Proc. Am. Soc. Clin. Oncol., 11: 184, 1992.
27. Wagener D.J.T., Verdonk H.E.R., Dirix L.Y., Catimel G., Siegenthaler P., Buitenhuis M., Mathieu-Bouè A., Verweij J.: Phase 11 trial of CPT11 in patients with advanced pancreatic cancer, an EORTC early clinical trial group study. Ann. Oncol. 6: 129-132, 1995.
28. Warshaw A.L., Fernandez Del Castillo C.: Pancreatic adenocarcinoma. N. Engl. J. Med., 326: 455-465, 1992.
29. Whitehead R.P., Jacobson J., Brown T.D., Taylor S.A., Weiss G.F., MacDonald J.S.: Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma. A Southwest Oncology Group study. J. Clin. Oncol., 15: 2414-2419, 1997.
30. Wils J.A., Kok T., Wagener D.J.T., Selleslags J., Duez N.: Activity of cisplatin in adenocarcinoma of the pancreas. Eur. J. Cancer, 2: 203-204, 1993.